Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab.

MLA

Tuckwell, Katie, et al. “Levels of CXCL13 and SICAM-1 Correlate with Disease Activity Score in Patients with Rheumatoid Arthritis Treated with Tocilizumab.” Advances in Rheumatology (London, England), vol. 59, no. 1, Dec. 2019, p. 54. EBSCOhost, https://doi.org/10.1186/s42358-019-0097-1.

APA

Tuckwell, K., Gabay, C., Sornasse, T., Laubender, R. P., Wang, J., & Townsend, M. J. (2019). Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab. Advances in Rheumatology (London, England), 59(1), 54. https://doi.org/10.1186/s42358-019-0097-1

Chicago

Tuckwell, Katie, Cem Gabay, Thierry Sornasse, Ruediger Paul Laubender, Jianmei Wang, and Michael J Townsend. 2019. “Levels of CXCL13 and SICAM-1 Correlate with Disease Activity Score in Patients with Rheumatoid Arthritis Treated with Tocilizumab.” Advances in Rheumatology (London, England) 59 (1): 54. doi:10.1186/s42358-019-0097-1.